Biospecimen Acquistion and Molecular Annotation

生物样本采集和分子注释

• 批准号: 8267641
• 负责人: Mark A. Watson
• 金额: $ 11.2万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8267641
• 关键词: Bioinformatics; Biostatistics Core; Clinical; Clinical Trials; Collection; Consent; Correlative Study; Data; Databases; Enrollment; Equipment and supply inventories; Extramural Activities; Generations; Genetic Polymorphism; Genomics; Goals; Institution; Molecular; Patient Recruitments; Patients; Plasma; Procedures; Process; Proteomics; Publishing; Research Infrastructure; Research Personnel; Resources; Sampling; Specimen; Specimen Handling; Stroke; Stroke prevention; Technology; Time; Tissue Banking; Tissue Banks; Tissues; Universities; Washington; base; data management; human disease; novel; quality assurance; web-accessible

Adavnces in genomic and proteomic technologies have made the availability of biospecimens and corresponding data critical to understanding the molecular basis of human diseases such as stroke. Accordingly, the goal of the Biospecimen Procurement Core is to collect, process, store, and distribute biospecimens from patients in the context of both this proposal's clinical trials and during the routine treatment of patients at this medicial center. The first aim of this core is to support the collection and processing of serum, plasma, CSF, and genomic DMA from patients (approximately 50 per year) enrolled in studies described in projects 1-3. Samples will be collected upon study entry and over multiple time points as permissable, to create a set of biospecimens that can be analyzed over time and correlated with clinical progression. When avaialble and appropriate, the core will also provide support to collect tissue specimens from patients. The second aim of this core is to create a more expansive biospecimen resource consisting of single time-point serum, plasma, and genomic DMA from all stroke patients (-800 per year) seen at this institution. The third aim of this core is to create an inventory of available biospecimen resources and deidentified data that can be accessed by authorized intramural and extramural SPOTRIAS investigators, for the purposes of sharing this biospecimen resource to promote novel clinical correlative studies in stroke prevention and treatment. To accomplish these goals, this core will capitalize on the extensive infrastructure that has already been developed for biospecimen management at our institution. Patient recruitment and consenting will be coordinated with Patient Core B. Biospecimens and associated data mangement will be coordinated with Biostatistics Core D and de-identified using a well-established honest broker mechanism. Specimen processing, storage, and quality assurance will utilize standardized operating procedures that have been in place in our institutional tissue bank for the past seven years. Generation and bioinformatic management of genomic polymorphism (SNP) data (although not specifically proposed in any of the current projects) will also be supported by the institution's GeneChip facility. Finally, biospecimen data management and data publishing will take advantage of efforts at our institution to develop an enterpriseclass, web-accessible biospecimen database (caTISSUE Core).

基因组学和蛋白质组学技术的进步使得生物标本和 这些数据对于理解中风等人类疾病的分子基础至关重要。 因此，生物标本采购核心的目标是收集、处理、存储和分发 在本提案的临床试验和常规试验期间， 在这个医疗中心治疗病人。这个核心的第一个目标是支持收集和 处理入组患者（每年约50例）的血清、血浆、CSF和基因组DNA， 项目1-3所述的研究。将在研究入组时和多个时间点采集样本 创建一组生物标本，可以随时间进行分析，并与临床相关 进展在可用和适当的情况下，核心还将为收集组织标本提供支持 从病人身上。该核心的第二个目标是创建一个更广泛的生物标本资源， 来自所有中风患者（每年约800例）的单一时间点血清、血浆和基因组DNA， 机构。该核心的第三个目标是创建可用生物标本资源的清单， 授权的校内和校外SPOTRIAS研究者可以访问的数据， 目的是共享这一生物标本资源，以促进新的中风临床相关研究 预防和治疗。为了实现这些目标，该核心将利用广泛的基础设施 已经在我们的研究机构中用于生物标本管理。患者招募和 同意将与患者核心B协调。生物标本和相关数据管理将 与生物统计核心D协调，并使用完善的诚实经纪人机制去识别。 标本处理、储存和质量保证将采用标准化操作程序， 已经在我们的组织库里保存了七年了生成和生物信息学 基因组多态性（SNP）数据的管理（尽管在当前的任何专利中都没有具体提出）。 项目）也将得到该机构基因芯片设施的支持。最后，生物样本数据 管理和数据发布将利用我们机构的努力来开发企业级， 可通过网络访问的生物样本数据库（caTISSUE Core）。